Microscope images were captured with a Nikon Eclipse E1000 using Meta-Morph software. the target RNA and an untethered RNA segment that serves as a binding platform for splicing factors. This study was designed to develop negatively acting bifunctional RNAs that recruit hnRNPA1 to exon 8 and block the general splicing machinery from your exon 8. By blocking the downstream splice site, this could competitively favor the inclusion ofSMNexon 7 and therefore increase full-length SMN production. Here we identify a bifunctional RNA that stimulated full-length SMN expression in a variety of cell-based assays including SMA patient fibroblasts. Importantly, this molecule was also able to induce SMN expression in a previously explained mouse model of SMA and demonstrates a novel therapeutic approach for SMA as well as a variety of diseases caused by a defect in splicing. == Introduction == Spinal muscular atrophy(SMA) is an autosomal recessive neuromuscular disorder and is the leading genetic cause of infant mortality. SMA has a carrier frequency of nearly 1 in 35 and an incidence of 1 1 in 6000 live births (Pearn,1980; Melki,1997). SMA is usually caused by the loss ofsurvival motor neuron-1(SMN1). In humans, a nearly identical copy gene, calledSMN2, is present, but this gene cannot compensate for the loss ofSMN1because of a single silent nucleotide difference inSMN2exon 7 (Lefebvreet al.,1997; Lorsonet al.,1999; Monaniet al.,1999). Echinomycin This single-nucleotide difference attenuates an exonic splice enhancer and at the same time creates an exonic splice silencer, resulting in the production of an alternatively spliced isoform lacking exon 7 (Cartegni and Krainer,2002; Kashima and Manley,2003; Kashimaet al.,2007). The majority ofSMN2-derived transcripts lack exon 7, and these transcripts produce an unstable protein called SMN7, which cannot provide protection from SMA development whenSMN1is not present (Lorson and Androphy,2000). SMNexon 7 is usually highly regulated by a complex cohort of positive and negative regulatorycisandtransfactors. SF2/ASF, a serinearginine (SR)-rich protein, has been shown to interact with an enhancer that overlaps the crucial C/T transition inSMNexon 7, and the protein is unable to bind the region in theSMN2context (Cartegni and Krainer,2002). The C/T transition not only disrupts the SF2/ASF enhancer, but it creates a novel hnRNPA1-dependent splicing silencer (Kashimaet al.,2007). Other SR or SR-like proteins such as hTra21, SRp30c, RBMY, and hnRNP-G have all been shown to associate either directly or indirectly withSMNexon 7 (Hofmannet al.,2000; Hofmann and Wirth,2002; Younget al.,2002). There are also severalcis-acting unfavorable regulatory regions that have been recognized that surroundSMNexon 7, including a negative Rabbit Polyclonal to MRGX1 element upstream and several unfavorable elements including the extended inhibitory context (Miyajimaet al.,2002; Singhet al.,2004ac,2007). Increasing expression fromSMN2, which is usually retained in essentially all SMA patients, may be a viable treatment option because none of the nonpolymorphic nucleotide differences betweenSMN1andSMN2alters the coding sequence when properly spliced. Echinomycin Several strategies have been employed toward this end. Stimulating theSMN2locus to increase total transcripts would increase SMN7 and full-length transcripts. Increasing both transcripts would be beneficial from a therapeutic perspective because the SMN7 protein product lessens the disease phenotype (Leet al.,2005). Pharmacologically increasing full-length SMN expression fromSMN2or alteringSMN2splicing to increase exon 7 inclusion has also been reported for a variety of compounds, including valproic acid, phenylbutyrate, polyphenol-based botanical compounds, hydroxyurea, suberoylanilide hydroxamic acid (SAHA), and quinazoline-based compounds (Andreassiet al.,2001,2004; Changet al.,2001; Lunnet al.,2004; Braheet al.,2005; Grzeschiket al.,2005; Jareckiet al.,2005; Kernochanet al.,2005; Brichtaet al.,2006; Avilaet al.,2007; Sakla and Lorson,2008; Thurmondet al.,2008). In addition, aminoglycosides, which can promote translational read-through of cellular stop codons, may show beneficial for therapy by stabilization of theSMN2-derived SMN protein (Wolstencroftet al.,2005; Mattiset al.,2006). Several nucleic-acid Echinomycin based SMA therapeutics have been developed that are designed to increase production of functional SMN protein by promoting inclusion ofSMN2exon 7 (Huaet al.,2007,2008). Oligonucleotide therapies that have been designed to block the exon 8 splice site increase splicing to exon 7 (Lim and Hertel,2001; Madocsaiet al.,2005). Novel peptidenucleic acids that comprise an exon 7 antisense domain name and a synthetic splicing-activation domain name peptide were shown to increaseSMN2exon 7 inclusion (Cartegni and.